Avecho Biotechnology Limited (AVE) Stock Statistics & Valuation Metrics

Avecho Biotechnology Limited has a market cap or net worth of AU$85.00M. The enterprise value is AU$82.85.

Avecho Biotechnology Limited has 3,863,725,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Avecho Biotechnology Limited’s return on equity (ROE) is -2.83 and return on invested capital (ROIC) is -64.50%.

The current PE Ratio of Avecho Biotechnology Limited is ―. Avecho Biotechnology Limited’s PEG ratio is -0.16.

In the last 12 months, Avecho Biotechnology Limited had revenue of 1.24M and earned -4.42M in profits. Earnings per share was >-0.01.

In the last 12 months, operating cash flow was -3.48M and capital expenditures -2.00K, giving a free cash flow of -3.48M billion.

Avecho Biotechnology Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Avecho Biotechnology Limited upcoming earnings date is Mar 3, 2027, TBA (Confirmed).

Avecho Biotechnology Limited as a current ratio of 9.95, with Debt / Equity ratio of 11.93%

In the past 12 months, Avecho Biotechnology Limited has paid -2.00M in taxes.

Avecho Biotechnology Limited EV to EBITDA ratio is -4.22, with an EV/FCF ratio of 22.44.

Avecho Biotechnology Limited has AU$6.61M in cash and marketable securities with AU$227.54K in debt, giving a net cash position of AU$6.38M billion.

Gross margin is 53.38%, with operating margin of -485.09%, and net profit margin of -356.82%.

The average price target for Avecho Biotechnology Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―